Lobbying Filing Details

Total Spending

$120,000

Activities

9

Lobbyists

4

Gov't Entities

36

Filing Information
Filing UUID:
d4163990-afa3-422d-bf3f-6cb1f0fa0629
Type:
Q1 - 1st Quarter - Report
Period:
2015 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 16, 2015 at 5:41 PM
Income:
$0
Expenses:
$120,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: William Wang
Registrant
JOHNS HOPKINS UNIVERSITY
BALTIMORE, Maryland
Client
JOHNS HOPKINS UNIVERSITY
Maryland, United States of America
Lobbying Activities (9)
Activity 1
Budget/Appropriations

Funding for National Institutes of Health; Ebola preparedness funding; FY16 appropriations

Lobbyists (3)
  • MELISA LINDAMOOD
  • MS. BETH ANN FELDER
  • JEFFREY GROSSI
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 2
Defense

Uniformed Services Family Health Plan

Lobbyists (1)
  • MELISA LINDAMOOD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 3
Education

Nurse training and student loans/scholarships

Lobbyists (1)
  • DAVID PARKER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 4
Foreign Relations

US-China higher education relations

Lobbyists (1)
  • JEFFREY GROSSI
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 5
Health Issues

Health care quality and safety; Ophthalmology injected device policy; nursing policy issues; alternatives to animal toxicity testing

Lobbyists (3)
  • MELISA LINDAMOOD
  • MS. BETH ANN FELDER
  • DAVID PARKER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 6
Medicare/Medicaid

Graduate medical education funding; Recovery audit contractors; Medicare physician payment - sustainable growth rate formula, H.R. 2 Medicare Acccess and CHIP Re-authorization; Children's Health Insurance Program; Medicare/Medicaid coverage issues, H.R. 605 Home Infusion Site of Care Act; Durable medical equipment competitive bidding, H.R. 2021 Protecting the Integrity of Medicare Act; Hospital readmissions policy, S.688/H.R. 1343 Establishing Beneficiary Equity in the Hospital Readmission Program Act; Reimbursement policy of pharmacy services, H.R. 592 Pharmacy and Medically Underserved Areas Enchancement Act; Innovation Grants

Lobbyists (3)
  • MELISA LINDAMOOD
  • MS. BETH ANN FELDER
  • DAVID PARKER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 7
Pharmacy

Pharmaceutical drug price increases; 340B drug discount program

Lobbyists (1)
  • MELISA LINDAMOOD
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 8
Science/Technology

Biomedical research and innovation; Intellectual property and patent policy; EPA research regulations and requirements, H.R. 1030 Secret Science Reform Act

Lobbyists (3)
  • MELISA LINDAMOOD
  • MS. BETH ANN FELDER
  • JEFFREY GROSSI
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 9
Taxation/Internal Revenue Code

New Markets Tax Credit

Lobbyists (1)
  • JEFFREY GROSSI
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
  • Centers For Medicare and Medicaid Services (CMS)

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.